Sign in

Trung Ho

Research Analyst at UBS Asset Management Americas Inc.

No public records or analyst profiles have been found for Trung Ho as an analyst at UBS. There is no evidence of a UBS analyst by this name with data on company coverage, performance track record, career timeline, or professional credentials. Without a confirmed identity, job title, or career details from LinkedIn or notable financial research platforms, a verified professional profile cannot be provided.

Trung Ho's questions to INSMED (INSM) leadership

Question · Q2 2025

Speaking on behalf of Trung Ho, an analyst asked about the potential read-through from the Birch (CRS) trial to the CEDAR (HS) trial and sought clarification on the endpoint for the CEDAR futility analysis.

Answer

CEO William Lewis expressed higher confidence in the Birch trial due to the biological similarity between CRS and bronchiectasis, calling HS a 'trickier disease' with more uncertainty. CMO Martina Flammer clarified that the CEDAR futility analysis will focus specifically on the primary endpoint: the percentage change in abscess and nodule count at week 16.

Ask follow-up questions

Fintool

Fintool can predict INSMED logo INSM's earnings beat/miss a week before the call

Let Fintool AI Agent track Trung Ho for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free